Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
cannabidiol
|
| gptkbp:approvalYear |
2018
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
N03AX24
|
| gptkbp:brand |
gptkb:Epidiolex
|
| gptkbp:chemicalClass |
Cannabis
|
| gptkbp:controlledSubstanceStatus |
not scheduled (US, as of 2020)
|
| gptkbp:countryOfOperation |
gptkb:European_Union
gptkb:United_States |
| gptkbp:form |
oral solution
|
| https://www.w3.org/2000/01/rdf-schema#label |
Epidiolex
|
| gptkbp:indication |
gptkb:tuberous_sclerosis_complex
gptkb:Dravet_syndrome gptkb:Lennox-Gastaut_syndrome |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:GW_Pharmaceuticals
|
| gptkbp:mechanismOfAction |
unknown
|
| gptkbp:pregnancyCategory |
not assigned (US)
|
| gptkbp:prescriptionStatus |
Rx only
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
diarrhea
fatigue elevated liver enzymes somnolence decreased appetite |
| gptkbp:bfsParent |
gptkb:CBD
|
| gptkbp:bfsLayer |
5
|